FDA Accuses uniQure of Data Manipulation for AMT-130; Legal Investigation Intensifies

Key Facts

1The FDA reportedly accused uniQure of pushing distorted and manipulated data for its AMT-130 drug.

2Law firm Hagens Berman is updating its securities class action investigation following a public rebuke of the company by federal officials.

3The AMT-130 drug was characterized as a "failed" product within the context of the accusations against the company.

The U.S. Food and Drug Administration (FDA) has reportedly accused biotechnology firm uniQure of presenting distorted and manipulated clinical data regarding its AMT-130 drug. Following these allegations, the law firm Hagens Berman announced an update to its ongoing securities class action investigation against the company. Federal officials issued a public rebuke, characterizing the AMT-130 product as a failure despite the company's previous representations to the market. The accusations suggest a significant breach of scientific integrity and potential efforts to mislead investors about the drug's true efficacy. This development poses a severe threat to uniQure’s market valuation and future regulatory prospects, as investor trust faces a sharp decline. Legal pressure continues to mount as shareholders seek accountability for the alleged misconduct.